MIT researchers found that benzo(a)pyrene plays a small part—about 11%—in the global risk of developing polycyclic aromatic hydrocarbons (PAHs)-associated cancer.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
